This “Neuropathic Pain - Pipeline Insight, 2021,” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Neuropathic Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Neuropathic Pain Understanding
Neuropathic Pain is caused by damage or injury to the nerves that transfer information between the brain and spinal cord from the skin, muscles and other parts of the body. The pain is usually described as a burning sensation and affected areas are often sensitive to the touch. Symptoms of Neuropathic Pain may also include excruciating pain, pins and needles, difficulty correctly sensing temperatures and numbness. Some people may find it hard to wear thick clothes as even slight pressure can aggravate the pain. Common causes of Neuropathic Pain include nerve pressure or nerve damage after surgery or trauma, viral infections, cancer, vascular malformations, alcoholism, neurological conditions such as multiple sclerosis and metabolic conditions such as diabetes. It may also be a side effect of certain medications. Occasionally no identifiable cause is found which can be distressing for the individual experiencing the pain. Chronic Neuropathic Pain is common and may be related to an underlying health condition such as cancer or diabetic neuropathy, or it could be related to treatments such as chemotherapy. The primary goals of treatment for Neuropathic Pain are to manage the pain as much as possible and to minimise the negative side effects of the treatment. Individuals with chronic Neuropathic Pain may be referred to a pain clinic for assessment, management and advice on living with chronic pain.
"Neuropathic Pain - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Neuropathic Pain pipeline landscape is provided which includes the disease overview and Neuropathic Pain treatment guidelines. The assessment part of the report embraces, in depth Neuropathic Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neuropathic Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Neuropathic Pain R&D. The therapies under development are focused on novel approaches to treat/improve Neuropathic Pain .
This segment of the Neuropathic Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
YHD1119, a controlled-release oral formulation of pregabalin, a gabapentinoid, for the treatment of neurological conditions is being developed by Yuhan. Currently, it is in Phase III stage of clinical trial evaluation to treat Peripheral Neuropathic Pain .
Algiax Pharmaceuticals has discovered AP-325, a unique proprietary small molecule drug compound, to treat Neuropathic Pain . AP-325 acts as a positive allosteric modulator (PAM) of the GABAA-receptor. GABAA receptor PAMs work via allosteric modulation: they do not bind at the same active site as the natural ligand Gamma-aminobutyric acid (GABAA) but affect the receptor by binding at a different site on the protein. AP-325 is designed to treat a large group of Neuropathic Pain patients and does not penetrate the brain as such there are no sedative actions that limit their use. Consequently, AP-325 as a non-opioid has a significantly lower potential for addiction or abuse and is truly unique because it is non-sedative, not centrally active and has a long-lasting efficacy. Currently, it is in Phase II stage of clinical trial evaluation to treat Peripheral Neuropathic Pain .
This segment of the report provides insights about the different Neuropathic Pain drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 80+ key companies which are developing the therapies for Neuropathic Pain . The companies which have their Neuropathic Pain drug candidates in the most advanced stage, i.e. phase II include, Algiax Pharmaceuticals.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Neuropathic Pain therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neuropathic Pain drugs.
Current Treatment Scenario and Emerging Therapies:
This product will be delivered within 3-5 business days.
Geography Covered
- Global coverage
Neuropathic Pain Understanding
Neuropathic Pain : Overview
Neuropathic Pain is caused by damage or injury to the nerves that transfer information between the brain and spinal cord from the skin, muscles and other parts of the body. The pain is usually described as a burning sensation and affected areas are often sensitive to the touch. Symptoms of Neuropathic Pain may also include excruciating pain, pins and needles, difficulty correctly sensing temperatures and numbness. Some people may find it hard to wear thick clothes as even slight pressure can aggravate the pain. Common causes of Neuropathic Pain include nerve pressure or nerve damage after surgery or trauma, viral infections, cancer, vascular malformations, alcoholism, neurological conditions such as multiple sclerosis and metabolic conditions such as diabetes. It may also be a side effect of certain medications. Occasionally no identifiable cause is found which can be distressing for the individual experiencing the pain. Chronic Neuropathic Pain is common and may be related to an underlying health condition such as cancer or diabetic neuropathy, or it could be related to treatments such as chemotherapy. The primary goals of treatment for Neuropathic Pain are to manage the pain as much as possible and to minimise the negative side effects of the treatment. Individuals with chronic Neuropathic Pain may be referred to a pain clinic for assessment, management and advice on living with chronic pain.
"Neuropathic Pain - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Neuropathic Pain pipeline landscape is provided which includes the disease overview and Neuropathic Pain treatment guidelines. The assessment part of the report embraces, in depth Neuropathic Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neuropathic Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Neuropathic Pain R&D. The therapies under development are focused on novel approaches to treat/improve Neuropathic Pain .
Neuropathic Pain Emerging Drugs Chapters
This segment of the Neuropathic Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Neuropathic Pain Emerging Drugs
YHD 1119: Yuhan
YHD1119, a controlled-release oral formulation of pregabalin, a gabapentinoid, for the treatment of neurological conditions is being developed by Yuhan. Currently, it is in Phase III stage of clinical trial evaluation to treat Peripheral Neuropathic Pain .
AP-325: Algiax Pharmaceuticals
Algiax Pharmaceuticals has discovered AP-325, a unique proprietary small molecule drug compound, to treat Neuropathic Pain . AP-325 acts as a positive allosteric modulator (PAM) of the GABAA-receptor. GABAA receptor PAMs work via allosteric modulation: they do not bind at the same active site as the natural ligand Gamma-aminobutyric acid (GABAA) but affect the receptor by binding at a different site on the protein. AP-325 is designed to treat a large group of Neuropathic Pain patients and does not penetrate the brain as such there are no sedative actions that limit their use. Consequently, AP-325 as a non-opioid has a significantly lower potential for addiction or abuse and is truly unique because it is non-sedative, not centrally active and has a long-lasting efficacy. Currently, it is in Phase II stage of clinical trial evaluation to treat Peripheral Neuropathic Pain .
Neuropathic Pain : Therapeutic Assessment
This segment of the report provides insights about the different Neuropathic Pain drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Neuropathic Pain
There are approx. 80+ key companies which are developing the therapies for Neuropathic Pain . The companies which have their Neuropathic Pain drug candidates in the most advanced stage, i.e. phase II include, Algiax Pharmaceuticals.
Phases
This report covers around 80+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Neuropathic Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Neuropathic Pain : Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Neuropathic Pain therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neuropathic Pain drugs.
Neuropathic Pain Report Insights
- Neuropathic Pain Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Neuropathic Pain Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Neuropathic Pain drugs?
- How many Neuropathic Pain drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Neuropathic Pain ?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Neuropathic Pain therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Neuropathic Pain and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Yuhan
- Algiax Pharmaceuticals
- Haisco Pharmaceutical Group Co., Ltd.
- Xalud Therapeutics, Inc.
- Bayer
- Novaremed Ltd.
- Eli Lilly and Company
- Aptinyx
- Toray Industries, Inc
- Allergan
- Lateral Pharma
- Eliem Therapeutics (UK) Ltd.
- SR419
- Biogen
- Lexicon Pharmaceuticals
- Flexion Therapeutics
- Neurofix S.L.
- Relmada Therapeutics, Inc.
- AlgoTherapeutix
- Abide Therapeutics
- SK biopharmaceuticals
- Kineta
- Shionogi
- Tools4Patient
- Newron Pharmaceuticals
- Fortovia Therapeutics
- Saniona
- Esteve
- OKYO Pharma
Key Products
- YHD 1119
- AP-325
- HSK16149
- XT-150
- BAY1817080
- NRD135S.E1
- LY3016859
- NYX-2925
- TRK-750
- onabotulinum toxin A
- LAT8881
- ONTOZRY
- KCP 506
- S 637880
- KRN 5500
- SAN 711
- E 52862
- ETX-018810
- T4P 1001
- SR419
- NW-1029
- BIIB074
- LX9211
- Amitriptyline
- ABX-1431
- REL-1017
- TV-45070
- NFX88
- Bam8-22 analogues
- OK 101
This product will be delivered within 3-5 business days.
Table of Contents
IntroductionExecutive Summary
Neuropathic Pain : Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Neuropathic Pain - Analytical Perspective
Late Stage Products (Phase III)
- Comparative Analysis
YHD 1119: Yuhan
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
AP-325: Algiax Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
SR419: SIMR Biotech
- Product Description
- Research and Development
- Product Development Activities
Preclinical and Discovery Stage Products
- Comparative Analysis
OK 101: OKYO Pharma
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Neuropathic Pain Key Companies
Neuropathic Pain Key Products
Neuropathic Pain - Unmet Needs
Neuropathic Pain - Market Drivers and Barriers
Neuropathic Pain - Future Perspectives and Conclusion
Neuropathic Pain Analyst Views
Neuropathic Pain Key Companies
AppendixList of Tables
Table 1 Total Products for Neuropathic Pain
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Neuropathic Pain
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Yuhan
- Algiax Pharmaceuticals
- Haisco Pharmaceutical Group Co., Ltd.
- Xalud Therapeutics, Inc.
- Bayer
- Novaremed Ltd.
- Eli Lilly and Company
- Aptinyx
- Toray Industries, Inc
- Allergan
- Lateral Pharma
- Eliem Therapeutics (UK) Ltd.
- SR419
- Biogen
- Lexicon Pharmaceuticals
- Flexion Therapeutics
- Neurofix S.L.
- Relmada Therapeutics, Inc.
- AlgoTherapeutix
- Abide Therapeutics
- SK biopharmaceuticals
- Kineta
- Shionogi
- Tools4Patient
- Newron Pharmaceuticals
- Fortovia Therapeutics
- Saniona
- Esteve
- OKYO Pharma
